The DOI matches its Crossref record; 114 of the 115 references it cites were found in a registry or an index.
Comparative efficacy of racemic ketamine and esketamine for depression: A systematic review and meta-analysis
Open accessAbstract
Background Ketamine appears to have a therapeutic role in certain mental disorders, most notably depression. However, the comparative performance of different formulations of ketamine is less clear.Objectives This study aimed to assess the comparative efficacy and tolerability of racemic and esketamine for the treatment of unipolar and bipolar major depression.Design Systematic review and meta-analysis.Data sources We searched PubMed, MEDLINE, Embase, PsycINFO, the Cochrane Central Register of Controlled Clinical Trials, and the Cochrane Database of Systematic Reviews for relevant studies published since database inception and December 17, 2019.Study eligibility criteria We considered randomized controlled trials examining racemic or esketamine for the treatment of unipolar or bipolar major depression.Outcomes Primary outcomes were response and remission from depression, change in depression severity, suicidality, retention in treatment, drop-outs, and drop-outs due to adverse events.Analysis Evidence from randomized controlled trials was synthesized as rate ratios (RRs) for treatment response, disorder remission, adverse events, and withdrawals and as standardized mean differences (SMDs) for change in symptoms, via random-effects meta-analyses.Findings 24 trials representing 1877 participants were pooled. Racemic ketamine relative to esketamine demonstrated greater overall response (RR = 3.01 vs. RR = 1.38) and remission rates (RR = 3.70 vs. RR = 1.47), as well as lower dropouts (RR = 0.76 vs. RR = 1.37).Conclusions Intravenous ketamine appears to be more efficacious than intranasal esketamine for the treatment of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“One meta-analysis found that racemic ketamine elicited a greater overall antidepressant response and had fewer dropouts across studies than esketamine [36].”
From Ketamine in neuropsychiatric disorders: an update (2024) · cites this paper as [36]
In the citing paper
“Notably, a recent meta-analysis has indicated significantly greater response (RR = 3.01 vs. RR = 1.38) and remission rates (RR = 3.70 vs. RR = 1.47), as well as lower dropouts (RR = 0.76 vs. RR = 1.37), favoring intravenous ketamine over intranasal esketamine [118].”
From Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression (2023) · cites this paper as [118]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
Liberati, A., Altman, D. G., Tetzlaff, J., Mulrow, C., Gøtzsche, P. C., Ioannidis, J. P. A., Clarke, M., Devereaux, P. J., Kleijnen, J., & Moher, D. (2009) · PLoS Medicine · doi:10.1371/journal.pmed.1000100 · Cited by 28,164
(1998) · The Journal of Clinical Psychiatry · Cited by 19,139
(1998) · PubMed · Cited by 10,216
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
Self-citationUtility of a new procedure for diagnosing mental disorders in primary care. The PRIME-MD 1000 study
Spitzer, R. L. (1994) · JAMA · doi:10.1001/jama.272.22.1749 · Cited by 2,648
Comparison of two methods to detect publication bias in meta-analysis.
Peters, J. L. (2006) · JAMA · doi:10.1001/jama.295.6.676 · Cited by 2,278
Utility of a New Procedure for Diagnosing Mental Disorders in Primary Care: The PRIME-MD 1000 Study
Spitzer, R. L. (1994) · JAMA · doi:10.1001/jama.1994.03520220043029 · Cited by 1,873
Charlson, F., van Ommeren, M., Flaxman, A., Cornett, J., Whiteford, H., & Saxena, S. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30934-1 · Cited by 1,702
Research works printed but not linked: 1
- Ochs-Ross, 2019, Efficacy and safety of esketamine nasal spray plus an oral antidepressant in elderly patients with treatment-resistant depression—TRANSFORM-3, Am. J. Geriatr. Psychiatry
Cited by
Sorted by citations
McIntyre, R. S., Rosenblat, J. D., Nemeroff, C. B., Sanacora, G., Murrough, J. W., Berk, M., Brietzke, E., Dodd, S., Gorwood, P., Ho, R., et al. (2021) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2020.20081251 · Cited by 731
Self-citationBlinding and expectancy confounds in psychedelic randomized controlled trials
Muthukumaraswamy, S. D., Forsyth, A., & Lumley, T. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933434 · Cited by 324
Ketamine and rapid antidepressant action: New treatments and novel synaptic signaling mechanisms
Krystal, J. H., Kavalali, E. T., & Monteggia, L. M. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01629-w · Cited by 262
Molecular mechanisms underlying the antidepressant actions of arketamine: beyond the NMDA receptor
Wei, Y., Chang, L., & Hashimoto, K. (2022) · Molecular Psychiatry · doi:10.1038/s41380-021-01121-1 · Cited by 248
Ketamine for the treatment of major depression: a systematic review and meta-analysis
Nikolin, S., Rodgers, A., Schwaab, A., Bahji, A., Zarate, C. A., Vázquez, G. H., & Loo, C. K. A. (2023) · EClinicalMedicine · doi:10.1016/j.eclinm.2023.102127 · Cited by 191
Self-citationAnhedonia and Depressive Disorders
Serretti, A. (2023) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.23.1086 · Cited by 169
Diagnosis and management of bipolar disorders
Goes, F. S. (2023) · BMJ · doi:10.1136/bmj-2022-073591 · Cited by 171
Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status
Henter, I. D., Park, L. T., & Zarate, C. A. (2021) · CNS Drugs · doi:10.1007/s40263-021-00816-x · Cited by 142
Self-citationThe molecular pathophysiology of depression and the new therapeutics
Tian, H., Hu, Z., Xu, J., & Wang, C. (2022) · MedComm · doi:10.1002/mco2.156 · Cited by 122
The antidepressant actions of ketamine and its enantiomers
Johnston, J. N., Henter, I. D., & Zarate, C. A. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108431 · Cited by 110
Self-citationKetamine in neuropsychiatric disorders: an update
Johnston, J. N., Kadriu, B., Kraus, C., Henter, I. D., & Zarate, C. A. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-023-01632-1 · Cited by 108
Self-citationVázquez, G. H., Bahji, A., Undurraga, J., Tondo, L., & Baldessarini, R. J. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211013579 · Cited by 95
Self-citationWu, F., Lu, Q.-B., Kong, Y., & Zhang, Z. (2023) · Neuroscience Bulletin · doi:10.1007/s12264-023-01052-7 · Cited by 93
Han, C., Ji, H., Guo, Y., Fei, Y., Wang, C., Yuan, Y., Ruan, Z., & Ma, T. (2023) · Drug Design Development and Therapy · doi:10.2147/dddt.s401161 · Cited by 92
Esketamine Treatment for Depression in Adults: A PRISMA Systematic Review and Meta-Analysis
Fountoulakis, K. N., Saitis, A., & Schatzberg, A. F. (2025) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20240515 · Cited by 90
Loo, C. K. A., Glozier, N., Barton, D., Baune, B. T., Mills, N. T., Fitzgerald, P. B., Glue, P., Sarma, S., Gálvez, V., Hadži-Pavlović, D., et al. (2023) · The British Journal of Psychiatry · doi:10.1192/bjp.2023.79 · Cited by 86
Kang, M. J. Y., Hawken, E., & Vazquez, G. H. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.860882 · Cited by 77
Bahji, A., Zarate, C. A., & Vázquez, G. H. (2022) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2022.2047928 · Cited by 76
Self-citationLi, X., Xiang, P., Liang, J., Deng, Y., & Du, J. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s356284 · Cited by 67
Ketamine for Bipolar Depression: A Systematic Review
Bahji, A., Zarate, C. A., & Vázquez, G. H. (2021) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyab023 · Cited by 70
Self-citationA unified model of ketamine’s dissociative and psychedelic properties
Marguilho, M., Figueiredo, I., & Castro-Rodrigues, P. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221140011 · Cited by 71
Ketamine as a therapeutic agent for depression and pain: mechanisms and evidence
Subramanian, S., Haroutounian, S., Palanca, B. J. A., & Lenze, E. J. (2022) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2022.120152 · Cited by 73
Leal, G. C., Souza-Marques, B., Mello, R. P., Bandeira, I. D., Caliman-Fontes, A. T., Carneiro, B. A., Faria-Guimarães, D., Guerreiro-Costa, L. N. F., Jesus-Nunes, A. P., Silva, S. S., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.151 · Cited by 62
Bahji, A., Pierce, M., Wong, J., Roberge, J. N., Ortega, I., & Patten, S. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.6614 · Cited by 60
Self-citationPettorruso, M., Guidotti, R., d’Andrea, G., Risio, L. D., D’Andrea, A., Chiappini, S., Carullo, R., Barlati, S., Zanardi, R., Rosso, G., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115378 · Cited by 60
The correlation of Esketamine with specific adverse events: a deep dive into the FAERS database
Jiang, Y., Du, Z., Shen, Y., Zhou, Q., & Zhu, H. (2023) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-023-01732-5 · Cited by 61
Ketamine and esketamine in suicidal thoughts and behaviors: a systematic review
Jollant, F., Colle, R., Nguyen, T. M. L., Corruble, E., Gardier, A. M., Walter, M., Abbar, M., & Wagner, G. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231151327 · Cited by 56
Solmi, M., Chen, C., Dauré, C., Buot, A., Ljuslin, M., Verroust, V., Mallet, L., Khazaal, Y., Rothen, S., Thorens, G., et al. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.09.004 · Cited by 62
Nogo, D., Jasrai, A. K., Kim, H., Nasri, F., Ceban, F., Lui, L. M. W., Rosenblat, J. D., Vinberg, M., Ho, R., & McIntyre, R. S. (2022) · Psychopharmacology · doi:10.1007/s00213-022-06105-9 · Cited by 54
Wan, X., Eguchi, A., Fujita, Y., Ma, L., Wang, X., Yang, Y. H., Qu, Y., Chang, L., Zhang, J., Mori, C., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109139 · Cited by 56
Hashimoto, K. (2024) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-024-01770-7 · Cited by 56
Zhu, M., Xu, S., Ju, X., Wang, S., & Yu, X. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s392784 · Cited by 53
d’Andrea, G., Pettorruso, M., Lorenzo, G. D., Rhee, T. G., Chiappini, S., Carullo, R., Barlati, S., Zanardi, R., Rosso, G., Nicola, M. D., et al. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.12.038 · Cited by 55
Feeney, A., & Papakostas, G. I. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2023.02.003 · Cited by 56
Saelens, J., Gramser, A., Watzal, V., Zarate, C. A., Lanzenberger, R., & Kraus, C. (2025) · Neuropsychopharmacology · doi:10.1038/s41386-024-02044-5 · Cited by 51
Self-citationRosenblat, J. D., deVries, F. E., Doyle, Z., McIntyre, R. S., Rodin, G., Zimmermann, C., Mak, E., Hannon, B. L., Schulz-Quach, C., Al-Kindy, A., et al. (2023) · Cancers · doi:10.3390/cancers15020400 · Cited by 51
The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence
Ragnhildstveit, A., Roscoe, J., Bass, L. C., Averill, C. L., Abdallah, C. G., & Averill, L. A. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231154125 · Cited by 53
Carron, M., Tamburini, E., Linassi, F., Pettenuzzo, T., Boscolo, A., & Navalesi, P. (2024) · British Journal of Anaesthesia · doi:10.1016/j.bja.2024.08.009 · Cited by 49
Pharmacotherapies Targeting GABA-Glutamate Neurotransmission for Treatment-Resistant Depression
Vecera, C. M., C. Courtes, A., Jones, G., Soares, J. C., & Machado-Vieira, R. (2023) · Pharmaceuticals · doi:10.3390/ph16111572 · Cited by 48
Constable, P. A., Al-Dasooqi, D., Bruce, R., & Senthil, M. P. (2022) · Clinical Optometry · doi:10.2147/opto.s355091 · Cited by 48
Duan, W., Peng, K., Qin, H.-M., Li, B.-M., Xu, Y.-X., Wang, D.-J., Yu, L., Wang, H., Hu, J., & Wang, Q. (2023) · British Journal of Anaesthesia · doi:10.1016/j.bja.2023.10.038 · Cited by 47
Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search
Bonaventura, J., Gomez, J. L., Carlton, M. L., Lam, S., Sánchez‐Soto, M., Morris, P. J., Moaddel, R., Kang, H. J., Zanos, P., Gould, T. D., et al. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01673-w · Cited by 47
Self-citationSubcutaneous Ketamine in Depression: A Systematic Review
Cavenaghi, V. B., da Costa, L. P., Lacerda, A. L. T., Hirata, E. S., Miguel, E. C., & Fráguas, R. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.513068 · Cited by 44
Ketamine, an Old–New Drug: Uses and Abuses
Vujović, K. S., Jotic, A. D., Medić, B., Srebro, D., Vujović, A., Žujović, J. T., Opanković, A., & Vučković, S. (2023) · Pharmaceuticals · doi:10.3390/ph17010016 · Cited by 45
Nikayin, S., Rhee, T. G., Cunningham, M. E., de Fontnouvelle, C. A., Ostroff, R. B., Sanacora, G., & Wilkinson, S. T. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.1074 · Cited by 42
Wang, W. T., Ling, B., Chen, Q., Xu, H., Lv, J., & Yu, W. (2023) · Medicine · doi:10.1097/md.0000000000033086 · Cited by 41
Real‐world effectiveness of repeated ketamine infusions for treatment‐resistant bipolar depression
Fancy, F., Rodrigues, N. B., Di Vincenzo, J. D., Chau, E. H., Sethi, R., Husain, M. I., Gill, H., Tabassum, A., Mckenzie, A., Phan, L., et al. (2023) · Bipolar Disorders · doi:10.1111/bdi.13284 · Cited by 40
Hashimoto, K., Zhao, M., Zhu, T., Wang, X., & Yang, J. (2024) · Journal of Anesthesia and Translational Medicine · doi:10.1016/j.jatmed.2024.07.001 · Cited by 38
Strumila, R., Nobile, B., Korsakova, L., Lengvenytė, A., Olié, É., López‐Castromán, J., Guillaume, S., & Courtet, P. (2021) · Pharmaceuticals · doi:10.3390/ph14121213 · Cited by 40
Ho, C. S. H., Tay, G. W. N., Wee, H. N., & Ching, J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24032231 · Cited by 37
Arketamine for bipolar depression: Open-label, dose-escalation, pilot study
Bandeira, I. D., Leal, G. C.-G., Correia‐Melo, F. S., Souza‐Marques, B., Silva, S. S., Lins-Silva, D. H., Mello, R. P., Vieira, F., Dorea-Bandeira, I., Faria-Guimarães, D., et al. (2023) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2023.06.028 · Cited by 36
Pharmacogenomics of ketamine: A systematic review
Meshkat, S., Rodrigues, N. B., Vincenzo, J. D. D., Ceban, F., Jaberi, S., McIntyre, R. S., Lui, L. M. W., & Rosenblat, J. D. (2021) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2021.11.036 · Cited by 36
Current perspectives on the diagnosis and management of fatigue in multiple sclerosis
Marchesi, O., Vizzino, C., Filippi, M., & Rocca, M. A. (2022) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2022.2106854 · Cited by 41
Ma, C.-B., Zhang, C.-Y., Gou, C.-L., Liang, Z., Zhang, J., Xing, F., Yuan, J., Wei, X., Zhang, Y., & Wang, Z. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s477342 · Cited by 34
Psychedelics in the treatment of unipolar and bipolar depression
Bosch, O. G., Halm, S., & Seifritz, E. (2022) · International Journal of Bipolar Disorders · doi:10.1186/s40345-022-00265-5 · Cited by 38
Terao, I., Tsuge, T., Endo, K., & Kodama, W. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.11.023 · Cited by 33
Autophagy: A New Mechanism for Esketamine as a Depression Therapeutic
Jiang, G., Wang, Y., Liu, Q., Gu, T., Liu, S., Yin, A., & Zhang, L. (2022) · Neuroscience · doi:10.1016/j.neuroscience.2022.05.014 · Cited by 33
Bahji, A., Bach, P., Danilewitz, M., Crockford, D. N., el‐Guebaly, N., Devoe, D. J. A., & Saitz, R. (2022) · Addiction · doi:10.1111/add.15853 · Cited by 36
Self-citationThe therapeutic role of ketamine and esketamine in treating psychopathological domains of depression
Jawad, M. Y., Vincenzo, J. D. D., Badulescu, S., Teopiz, K. M., Tabassum, A., Ceban, F., Mckenzie, A., Meshkat, S., Rosenblat, J. D., Ho, R., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.109299 · Cited by 32
Averbeck, B. B. (2022) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2121331119 · Cited by 37
The Quest for Secondary Pharmaceuticals: Drug Repurposing/Chiral-Switches Combination Strategy
D’Acquarica, I., & Agranat, I. (2023) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.2c00151 · Cited by 33
Pharmacologic approaches to suicide prevention
Zisook, S., Domingues, I., & Compton, J. (2023) · Focus · doi:10.1176/appi.focus.20220076 · Cited by 30
Willinger, D., Häberling, I. S., Ilioska, I., Berger, G. E., Walitza, S., & Brem, S. (2024) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2024.1386984 · Cited by 30
Chen, C., Zhou, N., Hu, N., Feng, J., & Wang, X. (2023) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s401032 · Cited by 37
Abuhelwa, A. Y., Somogyi, A. A., Loo, C. K. A., Glue, P., Barratt, D. T., & Foster, D. J. R. (2022) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2640 · Cited by 30
Bernardo, A. M., Lee, P., Marcotte, M. D., Mian, M. Y., Rezvanian, S., Sharmin, D., Kovačević, A., Savić, M. M., Cook, J. M., Sibille, E. L., et al. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01360-y · Cited by 30
Brendle, M., Robison, R. J., & Malone, D. C. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.09.083 · Cited by 29
Smith-Apeldoorn, S. Y., Veraart, J. K. E., Kamphuis, J., Spijker, J., van der Meij, A., van Asselt, A. D. I., Rot, M. A. H., & Schoevers, R. A. (2024) · Molecular Psychiatry · doi:10.1038/s41380-024-02478-9 · Cited by 32
Keeler, J. L., Treasure, J. L., Himmerich, H., Brendle, M., Moore, C., & Robison, R. J. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1181447 · Cited by 28
Bahji, A., & Mesbah-Oskui, L. (2021) · Journal of Affective Disorders · doi:10.1016/j.jad.2021.05.119 · Cited by 29
Self-citationBahji, A., Lunsky, I. O., Gutiérrez, G., & Vázquez, G. H. (2023) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2023.2278586 · Cited by 32
Self-citationHassan, K., Struthers, W. M., Sankarabhotla, A., & Davis, P. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.992624 · Cited by 31
Larrea, A., Sánchez-Sánchez, L., Díez-Martín, E., Elexpe, A., Torrecilla, M., Astigarraga, E., & Barreda‐Gómez, G. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13061727 · Cited by 28
(R)-ketamine ameliorates the progression of experimental autoimmune encephalomyelitis in mice
Wang, X., Chang, L., Tan, Y., Qu, Y., Shan, J., & Hashimoto, K. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.10.013 · Cited by 25
VanderZwaag, J., Halvorson, T., Dolhan, K., Šimončičová, E., Ben‐Azu, B., & Tremblay, M. (2022) · Neurochemical Research · doi:10.1007/s11064-022-03772-0 · Cited by 28
Halaris, A. E., & Cook, J. T. (2023) · Advances in experimental medicine and biology · doi:10.1007/978-981-19-7376-5_21 · Cited by 27
Mathai, D. S., Hull, T. D., Vando, L., & Malgaroli, M. (2024) · Journal of Affective Disorders · doi:10.1016/j.jad.2024.05.131 · Cited by 27
Jiang, M., Li, Q., Mao, M., Xu, C., Zhou, R., Wen, Y., Yuan, H., & Feng, S. (2023) · Journal of Affective Disorders · doi:10.1016/j.jad.2023.02.127 · Cited by 26
Sarasso, P., Billeci, M., Ronga, I., Raffone, F., Martiadis, V., & Petta, G. D. (2024) · Psychopathology · doi:10.1159/000539714 · Cited by 25
Esketamine combined with a mindfulness-based intervention for individuals with alcohol problems
Gent, E. M., Bryan, J., Cleary, M. A., Clarke, T. I., Holmwood, H. D., Nassereddine, R. O., Salway, C., Depla, S., Statton, S., Krecké, J., et al. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811241254834 · Cited by 26
Bayes, A. J., Short, B. L., Zarate, C. A., Park, L., Murrough, J. W., McLoughlin, D. M., Riva‐Posse, P., Schoevers, R. A., Veraart, J. K. E., Parikh, S. V., et al. (2022) · Journal of Affective Disorders · doi:10.1016/j.jad.2022.04.020 · Cited by 22
Self-citationSartim, A. G., Marques, J., Silveira, K. M., Gobira, P. H., Guimarães, F. S., Wegener, G., & Joca, S. R. L. (2021) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108679 · Cited by 22
The antidepressant effect and safety of non-intranasal esketamine: A systematic review
Smith-Apeldoorn, S. Y., Vischjager, M., Veraart, J. K. E., Kamphuis, J., Rot, M. A. H., & Schoevers, R. A. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811221084055 · Cited by 22
Low-dose esketamine improves acute postoperative pain in patients undergoing thoracoscopic surgery
Zhang, Q., Wang, X., Wang, Z.-Y., & Sun, H.-L. (2024) · Anesthesiology and Perioperative Science · doi:10.1007/s44254-023-00039-x · Cited by 21
Ketamine and esketamine for crisis management in patients with depression: Why, whom, and how?
Lengvenytė, A., Strumila, R., Olié, É., & Courtet, P. (2022) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2022.02.004 · Cited by 21
Pilc, A., Machaczka, A., Kawalec, P., Smith, J. L., & Witkin, J. M. (2022) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2111415 · Cited by 21
Overcoming the myths of esketamine administration: different and not difficult
Buchmayer, F., & Kasper, S. F. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1279657 · Cited by 22
Yrondi, A., Javelot, H., Nobile, B., Boudieu, L., Aouizerate, B., Llorca, P., Charpeaud, T., Bennabi, D., Antoine Lefrere, A., & Samalin, L. (2024) · L Encéphale · doi:10.1016/j.encep.2023.11.029 · Cited by 22
Vasiliu, O. (2023) · Pharmaceuticals · doi:10.3390/ph16030411 · Cited by 20
Psychedelic medicines for end-of-life care: Pipeline clinical trial review 2022
Jing, X., Hoeh, N. R., & Menkes, D. B. (2023) · Palliative & Supportive Care · doi:10.1017/s147895152300069x · Cited by 17
Oral ketamine may offer a solution to the ketamine conundrum
Dutton, M., Can, A., Lagopoulos, J., & Hermens, D. F. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06480-x · Cited by 21
Ketamine cystitis following ketamine therapy for treatment-resistant depression – case report
Chang, M., Juruena, M. F., & Young, A. H. (2024) · BMC Psychiatry · doi:10.1186/s12888-023-05468-3 · Cited by 19
Ip, C.-T., de Bardeci, M., Kronenberg, G., Pinborg, L. H., Seifritz, E., Brunovský, M., & Olbrich, S. (2024) · Translational Psychiatry · doi:10.1038/s41398-024-02761-x · Cited by 18
Gutiérrez, G., Swainson, J., Ravindran, N., Lam, R. W. M., Giacobbe, P., Ganapathy, K., Kowara, A., Do, A., Baskaran, A., Nestor, S. M., et al. (2024) · Psychiatry Research · doi:10.1016/j.psychres.2024.116125 · Cited by 19
Patents on Psychedelics: The Next Legal Battlefront of Drug DevelopmentPreprint
Marks, M., & Cohen, I. G. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3948757 · Cited by 19
Liu, P., Zhang, S., Liang, Y., Gao, Z., Gao, W., & Dong, B. (2022) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s388764 · Cited by 19
Dose‐dependent effects of esketamine on brain activity in awake mice: A BOLD phMRI study
Kawazoe, K., McGlynn, R. P., Felix, W., Sevilla, R. S., Liao, S., Kulkarni, P., & Ferris, C. F. (2022) · Pharmacology Research & Perspectives · doi:10.1002/prp2.1035 · Cited by 18
Yang, T., Mudabbar, M. S., Liu, B., Xu, M., & Fu, Q. (2023) · Obesity Surgery · doi:10.1007/s11695-023-06676-2 · Cited by 18
Transcranial magnetic stimulation and ketamine: implications for combined treatment in depression
Dębowska, W., Więdłocha, M., Dębowska, M. D., Kownacka, Z., Marcinowicz, P., & Szulc, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1267647 · Cited by 23
Wen, Y., Mao, M., Jiang, M., Liu, Q., Li, Q., Wang, X., Yuan, H., Wang, X., & Feng, S. (2024) · International Journal of Surgery · doi:10.1097/js9.0000000000001870 · Cited by 18
Metadata
- Authors
- Bahji, A., Vazquez, G. H., & Zarate, C. A.
- Affiliations
- Queen's University (CA)
- National Institutes of Health (US)
- Corresponding author
- Zarate, Carlos A.
- Venue
- Journal of Affective Disorders
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 278
- Pages
- 542-555
- ISSN
- 0165-0327 (ISSN-L)
- PMC
- PMC7704936
- OpenAlex
- W3088001093
- Cited by
- 408
- References
- 115
- Citations by year
- 2026: 46 · 2025: 76 · 2024: 87 · 2023: 85 · 2022: 79 · 2021: 31
- FWCI
- 6.49
- Type
- journal article
- Language
- en
- Update notices
- erratum (2021-02-15)
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Journal of Affective Disorders (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute of Mental Health
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
- Life Sciences › Neuroscience › Neurology › Transcranial Magnetic Stimulation Studies
- Keywords
- ketamine, esketamine, racemic ketamine, major depressive disorder, bipolar depression, treatment response, remission, treatment discontinuation, adverse events, suicidality, intravenous administration, intranasal administration, drug efficacy comparison
- MeSH terms
- Antidepressive Agents, Depression, Depressive Disorder, Major, Major Depressive Disorder, Humans, Ketamine
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
